HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Clarins’ buyback succeeds

This article was originally published in The Rose Sheet

Executive Summary

Financiére FC, a holding company owned by the Courtin-Clarins family, has bought back enough shares to delist Groupe Clarins from the Paris Bourse, French market regulator Autorité des Marchés Financiers (AMF) says in Sept. 24 release. At close of the buyback offer Sept. 16, Financiére FC reportedly owned 96.44% of Clarins' capital and 97.2% of voting rights, clearing 95% threshold required by AMF. Consistent with price set when buyback plan was announced earlier this year, company will purchase remaining 2.21% of Clarins capital for €55.50 per share. Clarins brothers said roughly $1.17 billion would be invested in taking company private, a move that will grant it the stability needed to execute its strategic vision (1"The Rose Sheet" Aug. 11, 2008, p. 5)

You may also be interested in...



Clarins Has Go-Ahead To Buy Out Minority Shareholders, Lowers 2008 Guidance

The Courtin-Clarins family's plan to repurchase all outstanding Groupe Clarins shares and delist from the French stock market has gotten the green light from regulator Autorité des Marchés Financiers (AMF)

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel